IR@PKUHSC  > 北京大学基础医学院  > 药理学系
学科主题基础医学
PPAR gamma Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice
Sun, Ying1,2,3; Jia, Zhanjun2,3; Liu, Gang2,3; Zhou, Li2,3; Liu, Mi2,3; Yang, Baoxue1; Yang, Tianxin2,3,4,5
刊名PPAR RESEARCH
2013
DOI10.1155/2013/612971
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental
研究领域[WOS]Research & Experimental Medicine
关键词[WOS]PROSTAGLANDIN-E RECEPTORS ; DIABETIC-NEPHROPATHY ; GLYBURIDE MONOTHERAPY ; METABOLIC SYNDROME ; LEPTIN RECEPTOR ; TYPE-2 ; KIDNEY ; E-2 ; STREPTOZOTOCIN ; ALBUMINURIA
英文摘要

Evidence had shown the detrimental effect of prostaglandin (PG) E2 in diabetic nephropathy (DN) of STZ-induced type-1 diabetes but its role in the development of DN of type-2 diabetes remains uncertain. The present study was undertaken to investigate the regulation of PGE2 synthetic pathway and the interaction between peroxisome proliferator-activated receptor (PPAR)gamma and PGE2 synthesis in the kidneys of db/db mice. Strikingly, urinary PGE2 was remarkably elevated in db/db mice paralleled with the increased protein expressions of COX-2 and mPGES-1. In contrast, the protein expressions of COX-1, mPGES-2, cPGES, and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) were not altered. Following 1-week rosiglitazone (Rosi) therapy, urinary PGE2, but not other prostanoids, was reduced by 57% in parallel with significant reduction of mPGES-1 protein and EP4 mRNA expressions. By immunohistochemistry, mPGES-1 was significantly induced in the glomeruli of db/db mice, which was almost entirely abolished by Rosi. In line with the reduction of glomerular mPGES-1, the glomerular injury score showed a tendency of improvement after 1 week of Rosi therapy. Collectively, the present study demonstrated an inhibitory effect of PPAR gamma activation on renal mPGES-1/PGE2/EP4 pathway in type-2 diabetes and suggested that mPGES-1 may potentially serve as a therapeutic target for treating type-2 diabetes-associated DN.

语种英语
WOS记录号WOS:000329627500001
项目编号DK079162 ; 11SDG7480006
资助机构VA Merit Review ; National Institutes of Health
引用统计
被引频次:6[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56198
专题北京大学基础医学院_药理学系
北京大学口腔医学院_消毒供应中心
北京大学临床肿瘤学院_VIP-Ⅱ
作者单位1.Vet Affairs Med Ctr, Salt Lake City, UT 84148 USA
2.Vet Affairs Med Ctr, Salt Lake City, UT 84132 USA
3.Peking Univ, Dept Pharmacol, Sch Basic Med Sci, Beijing 100191, Peoples R China
4.Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA
5.Univ Utah, Div Nephrol & Hypertens, Salt Lake City, UT 84132 USA
推荐引用方式
GB/T 7714
Sun, Ying,Jia, Zhanjun,Liu, Gang,et al. PPAR gamma Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice[J]. PPAR RESEARCH,2013.
APA Sun, Ying.,Jia, Zhanjun.,Liu, Gang.,Zhou, Li.,Liu, Mi.,...&Yang, Tianxin.(2013).PPAR gamma Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice.PPAR RESEARCH.
MLA Sun, Ying,et al."PPAR gamma Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice".PPAR RESEARCH (2013).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
PPAR gamma Agonist R(3738KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Ying]的文章
[Jia, Zhanjun]的文章
[Liu, Gang]的文章
百度学术
百度学术中相似的文章
[Sun, Ying]的文章
[Jia, Zhanjun]的文章
[Liu, Gang]的文章
必应学术
必应学术中相似的文章
[Sun, Ying]的文章
[Jia, Zhanjun]的文章
[Liu, Gang]的文章
相关权益政策
暂无数据
收藏/分享
文件名: PPAR gamma Agonist Rosiglitazone Suppresses Renal mPGES-1_PGE2 Pathway in db_db Mice.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。